PPARGC1A and chronic kidney disease: It is reported that, in rat CKD models, the GLP-1R agonist Liraglutide could improve the mitochondrial function of renal cells by activating the SIRT1/AMPK/PGC1α pathway, and reduce lipid accumulation in the kidney (43).